KLDO News and Press, Kaleido Biosciences Inc. From 07/22/21

Seres Therapeutics (MCRB) -57% after mid-stage ulcerative colitis study fails main goal.Jupiter Wellness (JUPW) -24% after raises $32.5M capital via stock and warrants offering.TRACON Pharmaceuticals (TCON) -23% after securing $15M capital raise.NETGEAR (NTGR)&#x...

U.S. clinical-stage healthcare company Kaleido Biosciences (KLDO) is trading higher pre-market after announcing the appointment of Jerald Korn as Chief Operating Officer, effective July 1, 2021.Korn will take the new role in addition to his ongoing role of General Counsel and Corporate Secret...

Gainers: Osmotica Pharmaceuticals (OSMT) +38%, Star Equity (STRR) +16%, Atossa Therapeutics (ATOS) +15%, Vor Biopharma (VOR) +12%, Rezolute (RZLT) +10%.Losers: Theravance Biopharma (TBPH) -8%, Corbus Pharmaceuticals (CRBP) -8%, Kaleido Bi...

Gainers: Kaleido Biosciences (KLDO) +15%, Pieris Pharmaceuticals (PIRS) +14%, Arcus Biosciences (RCUS) +14%, Compugen (CGEN) +14%, Atossa Therapeutics (ATOS) +14%.Losers: Portage Biotech (PRTG) -23%, Rite Aid (RAD) -14%, 4D Mole...

If you're looking for a second opinion on your stocks, look no further than our proprietary POWR Ratings. Our ratings evaluate stock based on 118 different factors. Stocks that were downgraded to a Sell or Strong Sell such as SunPower Corporation (SPWR), Kaleido Biosciences (KLDO), and Ocugen...

LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella w...

The stock market's attempt to make new highs was rejected this morning. Sometimes, this can lead to additional selling pressure. Certain stocks are more vulnerable in this environment. Find out why Kaleido Biosciences (KLDO), Vislink Technologies (VISL) and Verb Technology Company (VERB) shou...

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...

Kaleido Biosciences (KLDO): Q1 GAAP EPS of -$0.58 misses by $0.01.As of March 31, 2021, the Company reported cash and cash equivalents of $92.4 million. The Company continues to manage its operating expenses and, as a result, has cash runway into the first quarter of 2022.Press Release For ...